Alkermes plc Stock
Price
Target price
€27.00
€27.00
-1.460%
-0.4
-1.460%
€37.60
05.06.25 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Alkermes plc Stock
A loss of -1.460% shows a downward development for Alkermes plc.
Alkermes plc is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
As a result the target price of 37 € shows a positive potential of 37.04% compared to the current price of 27.0 € for Alkermes plc.
Pros and Cons of Alkermes plc in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | -1.460% | 1.504% | 1.504% | 21.622% | -3.571% | -0.626% | 81.208% |
| Icon plc | 0.930% | 6.411% | 2.607% | -58.770% | -40.633% | -41.346% | - |
| Arrowhead Pharmaceuticals Inc. | 3.230% | 4.206% | 28.285% | -35.037% | -20.303% | -54.555% | -51.135% |
| Ironwood Pharmaceuticals | -7.170% | -10.545% | -38.500% | -91.517% | -88.286% | -95.256% | -94.472% |
Comments
Alkermes plc (NASDAQ: ALKS) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $45.00 price target on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Robert W. Baird from $38.00 to $41.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $40.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Plc EPS Soars Past Forecasts
Alkermes (NASDAQ:ALKS), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported
